HighTower Advisors’s Lipocine LPCN Stock Holding History

HighTower Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-588	Closed	-$14K	–	3176
2020 Q4	$14K	Hold	588	–	–	﹤0.01%	2503
2020 Q3	$14K	Buy	+588	New	+$15.6K	﹤0.01%	2392

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HighTower Advisors's LPCN Position: Q1 2021 in Review

HighTower Advisors sold out of Lipocine (LPCN) in Q1 2021, closing a stake of 588 shares — an estimated $14K sold.

HighTower Advisors first reported a position in LPCN in Q3 2020 and held it in 2 quarters. The position peaked at $14K in Q4 2020. 42 funds tracked by Wall St. Rank hold LPCN as of Q1 2021.

HighTower Advisors reported no remaining Lipocine position as of Q1 2021 after selling out during the quarter.
HighTower Advisors sold 588 Lipocine shares in Q1 2021, an estimated $14K.
HighTower Advisors first reported a position in Lipocine in Q3 2020 and held it in 2 quarters.
HighTower Advisors's Lipocine position peaked at $14K in Q4 2020.
42 funds tracked by Wall St. Rank held Lipocine as of Q1 2021.

Based on HighTower Advisors's 13F filing for Q1 2021, filed 10 May 2021.